More money than sense

Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.
15 Oct 2008

Liquidity? Go west…

UK biotech Phynova makes a business out of developing traditional medicines, but when it comes to raising money it is pioneering a new, low-cost route to American investors.
02 Apr 2008